OncoMatch/Clinical Trials/NCT03937544
Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL
Is NCT03937544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2/3 trial studies multiple treatments including CD19 CAR-T CELLS and Cyclophosphamide for relapsed b acute lymphoblastic leukaemia.
Treatment: CD19 CAR-T CELLS · Cyclophosphamide · Fludarabine — This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute Lymphoblastic Leukaemia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: immunotherapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: allogeneic cellular therapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Cannot have received: anti-GVHD therapy
Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy weeks, anti-GVHD therapy.
Lab requirements
Kidney function
creatinine clearance > 50 ml/min
Liver function
serum total bilirubin < 5 times the normal value
Cardiac function
left ventricular ejection fraction > 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03937544 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, immunotherapy, allogeneic cellular therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 13 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages